Victory Capital Management’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-6,034
| Closed | -$208K | – | 2619 |
|
|
2020
Q3 | $208K | Sell |
6,034
-2,064,497
| -100% | -$44M | ﹤0.01% | 2275 |
|
|
2020
Q2 | $34.6M | Sell |
2,070,531
-1,703,721
| -45% | -$28.9M | 0.05% | 557 |
|
|
2020
Q1 | $54.4M | Buy |
3,774,252
+1,635,064
| +76% | +$41.8M | 0.05% | 542 |
|
|
2019
Q4 | $71.6M | Buy |
2,139,188
+648,313
| +43% | +$18.1M | 0.09% | 335 |
|
|
2019
Q3 | $31.2M | Buy |
1,490,875
+369,064
| +33% | +$7.53M | 0.04% | 630 |
|
|
2019
Q2 | $23.4M | Buy |
1,121,811
+26,690
| +2% | +$549K | 0.05% | 559 |
|
|
2019
Q1 | $24.5M | Buy |
1,095,121
+145,060
| +15% | +$3.42M | 0.06% | 519 |
|
|
2018
Q4 | $22.7M | Buy |
950,061
+240,310
| +34% | +$6.22M | 0.06% | 508 |
|
|
2018
Q3 | $19.4M | Buy |
709,751
+23,270
| +3% | +$658K | 0.04% | 615 |
|
|
2018
Q2 | $18.5M | Buy |
686,481
+21,840
| +3% | +$668K | 0.04% | 622 |
|
|
2018
Q1 | $21.2M | Buy |
664,641
+600,510
| +936% | +$21.1M | 0.05% | 572 |
|
|
2017
Q4 | $2.42M | Buy |
64,131
+7,830
| +14% | +$253K | 0.01% | 970 |
|
|
2017
Q3 | $1.4M | Buy |
56,301
+8,010
| +17% | +$173K | ﹤0.01% | 1123 |
|
|
2017
Q2 | $993K | Sell |
48,291
-680
| -1% | -$13K | ﹤0.01% | 1187 |
|
|
2017
Q1 | $1.06M | Buy |
+48,971
| New | +$1M | ﹤0.01% | 1150 |
|
|
2016
Q4 | – | Sell |
-38,570
| Closed | -$579K | – | 1841 |
|
|
2016
Q3 | $579K | Buy |
+38,570
| New | +$521K | ﹤0.01% | 1215 |
|
Victory Capital Management's AIMT Position: Q4 2020 in Review
Victory Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 6,034 shares — an estimated $208K sold.
Victory Capital Management first reported a position in AIMT in Q3 2016 and held it in 16 quarters. The position peaked at $71.6M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Victory Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Victory Capital Management sold 6,034 Aimmune Therapeutics shares in Q4 2020, an estimated $208K.
- Victory Capital Management first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 16 quarters.
- Victory Capital Management's Aimmune Therapeutics position peaked at $71.6M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Victory Capital Management's 13F filing for Q4 2020, filed 1 Feb 2021.